Business Context and Reporting Period
This Form 8-K reports on the results of the 2015 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on June 8, 2015. The meeting took place at the company's principal executive offices in Beverly Hills, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 11,849,080 shares (of 16,223,281 entitled to vote) participated in the meeting. Two proposals were approved:
- Election of Directors: Nine nominees were elected to the Board of Directors to serve until the 2016 annual meeting. The nominees included Frank Litvack, M.D., Linda Marbán, Ph.D., David B. Musket, George W. Dunbar, Jr., Louis Manzo, Louis J. Grasmick, Earl M. (Duke) Collier, Jr., Gregory W. Schafer, and Joshua Kazam. All received significant "For" votes, with "Broker Non-Votes" totaling 2,536,498 for each nominee.
- Ratification of Auditors: The appointment of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015, was ratified. The vote count was 11,846,545 "For," 482 "Against," and 2,053 "Abstain."
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves solely as a disclosure of the voting outcomes.
Investor Verification Checklist
- Verify the composition of the newly elected Board of Directors against the company's latest proxy statement.
- Confirm the engagement of Rose, Snyder & Jacobs LLP for the 2015 fiscal year audit.
- Note the high number of broker non-votes (2,536,498) regarding the director elections, indicating shares held in street name where brokers did not have discretionary voting authority.